Metsera falls sharply after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 ...

NVIDIA GTC Paris at VivaTech - NVIDIA today announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases.

The S&P 500 (SP500) closed in the red on Friday, with Nasdaq (COMP:IND) falling 2.8% during the week. Wall Street had a slew of upgrades and downgrades from analysts. Here are some of the major calls ...

Novo Nordisk(NYSE: NVO) is in the spotlight after cutting guidance again, but analysts remain optimistic. With Ozempic and Wegovy driving strong sales and a 52% upside potential, this could be one of ...

Novo Nordisk (NYSE:NVO) climbs about 2% on Monday afternoon after it says it will not raise its offer for Metsera ...

Novo Nordisk's softening sales performance, which prompted restructuring, has resulted in significantly reduced profit ...

Wondering if Novo Nordisk shares are a bargain or overpriced? You are not alone, especially with so much buzz around healthcare leaders these days. After surging for several years, Novo Nordisk stock ...

Novo Nordisk maintains strong growth prospects, driven by obesity treatment market expansion. See why NVO stock is a strong ...

Wegovy’s key competitor is Eli Lilly’s GLP-1 drug Mounjaro (tirzepatide), which became India’s top-selling medicine in ...

Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity ...

Newly-elected chairman of Wegovy-maker Novo Nordisk , Lars Rebien Sorensen, said on Friday he plans to enhance the board's ...

Day in and day out, companies continue to clamor for the NVIDIA GPUs that are powering the AI revolution. Here are some of the big collaborations and partnerships that the company has announced (so ...